首页|自拟复方丹参方联合芦可替尼治疗骨髓纤维化患者的临床疗效及对其生活质量的影响

自拟复方丹参方联合芦可替尼治疗骨髓纤维化患者的临床疗效及对其生活质量的影响

扫码查看
目的 探究自拟复方丹参方联合芦可替尼治疗骨髓纤维化患者的临床疗效及对其生活质量的影响.方法 选取2017年10月—2020年12月期间邢台市第一医院收治的90例骨髓纤维化患者,根据随机数字表法分为对照组和研究组,每组各45例.对照组给予磷酸芦可替尼片治疗,研究组在对照组基础上联合复方丹参方治疗,两组患者均治疗6个月.观察比较两组患者临床疗效、骨髓纤维化改善率、不良反应发生率,治疗前后骨髓增殖性肿瘤总症状评估量表(Myeloproliferative neoplasm symptom assessment form,MPN-SAF-TSS)评分、脾脏大小(脾脏的长径、厚径)、血常规指标[白细胞计数(White blood cell count,WBC)、血小板(Platelet,PLT)、血红蛋白(Hemoglobin,Hb)]及生活质量评分.结果 治疗后研究组有效率75.56%(34/45)明显高于对照组55.56%(25/45),差异有统计学意义(P<0.05).治疗后研究组骨髓纤维化改善率64.44%(29/45)明显高于对照组42.22%(19/45),差异有统计学意义(P<0.05).治疗后两组患者MPN-SAF-TSS评分均较治疗前降低,差异有统计学意义(P<0.05);且研究组MPN-SAF-TSS评分明显低于对照组,差异有统计学意义(P<0.05).治疗后两组患者脾脏的长径和厚径均较治疗前减小,差异有统计学意义(P<0.05);且研究组脾脏的长径和厚径均明显小于对照组,差异有统计学意义(P<0.05).治疗后两组患者WBC、PLT水平均较治疗前降低,Hb水平均较治疗前升高,差异有统计学意义(P<0.05);且研究组WBC、PLT水平均明显低于对照组,Hb水平明显高于对照组,差异有统计学意义(P<0.05).治疗后两组患者QOL评分均较治疗前升高,差异有统计学意义(P<0.05);且研究组QOL评分明显高于对照组,差异有统计学意义(P<0.05).治疗期间,研究组不良反应发生率17.78%(8/45)与对照组20.00%(9/45)比较,差异无统计学意义(P>0.05).结论 自拟复方丹参方联合芦可替尼治疗骨髓纤维化可减轻患者临床症状,缩小脾脏,改善血常规指标,降低骨髓纤维化程度,提高生活质量,安全性高.
Clinical Efficacy of Self-made Compound Danshen Formula Combined with Rux-olitinib in Treatment of Patients with Myelofibrosis and Its Influence on Quality of Life
Objective To investigate the clinical efficacy of self-formulated Compound Danshen Formula com-bined with ruxolitinib in the treatment of patients with myelofibrosis and its impact on their quality of life(QOL).Methods Ninety patients with myelofibrosis who were admitted to The First Hospital of Xingtai between October 2017 and December 2020 were selected and randomly divided into a control group and a study group according to a random number table,with 45 patients in each group.The control group was treated with ruxolitinib phosphate tablets,while the study group received the Compound Danshen Formula in addition to the treatment given to the control group.Both groups were treated for six months.The clinical efficacy,improvement rate of myelofibrosis,incidence of adverse reactions,pre-and post-treatment scores on the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score(MPN-SAF-TSS),spleen size(length and thickness),blood routine indices[white blood cell count(WBC),platelet(PLT),hemoglobin(Hb)],and QOL scores were observed and compared between the two groups.Results After treatment,the effective rate in the study group was 75.56%(34/45),significantly higher than 55.56%(25/45)in the control group(P<0.05).The improvement rate of myelofibrosis in the study group was 64.44%(29/45),significantly higher than 42.22%(19/45)in the control group(P<0.05).Post-treatment MPN-SAF-TSS scores were significantly lower in both groups compared to pre-treatment(P<0.05).The MPN-SAF-TSS score of the study group was significantly lower than that of the control group(P<0.05).The length and thickness of the spleen in both groups were significantly reduced post-treatment compared to pre-treatment(P<0.05).The spleen length and thickness of the study group were significantly smaller than those of the control group(P<0.05).Post-treatment WBC and PLT levels were significantly lower,and Hb levels were significantly higher in both groups compared to those before treatment(P<0.05).The WBC and PLT levels of the study group were significantly lower,and Hb levels were significantly higher than those of the control group(P<0.05).Post-treatment QOL scores were significantly higher in both groups compared to those before treatment(P<0.05).The QOL scores of the study group were significantly higher than those of the control group(P<0.05).During the treatment period,the incidence of adverse reactions was 17.78%(8/45)in the study group and 20.00%(9/45)in the control group,with no statistically significant difference(P>0.05).Conclusion The combination of the self-formulated Compound Danshen Formula with ruxolitinib in the treatment of myelofibrosis can alleviate clinical symptoms,reduce spleen size,improve blood routine indi-ces,decrease the degree of myelofibrosis,enhance QOL,and is highly safe.

Danshen(Salviae Miltiorrhizae Radix et Rhizoma)Chinese Medicine PrescriptionRuxolitinibMy-elofibrosis

杨艳敏、郝秀君、赵志芳、王佩、徐伟格、董照、原现华

展开 >

邢台医学高等专科学校第一附属医院/邢台市第一医院血液病科,河北邢台 054000

丹参 中药组方 芦可替尼 骨髓纤维化

邢台市重点研发计划自筹项目任务书

2020ZC288

2024

世界中西医结合杂志
中华中医药学会

世界中西医结合杂志

CSTPCD
影响因子:1.053
ISSN:1673-6613
年,卷(期):2024.19(9)
  • 11